as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹1,722.3
Change
+64.0 (3.86%)
Open
₹1,658.3
Prev. Close
₹1,658.3
Day High
₹1,745.1
Day Low
₹1,650.8
Volume Analysis
Traded
152,518
Delivered
87,779
Delivery %
57.55%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (27.0%)
- •Strong operating margin (24.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year revenue growth (64.5%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,855.64 | ₹1,800.37 | ₹1,761.34 | ₹1,706.07 | ₹1,667.04 | ₹1,611.77 | ₹1,572.74 |
| Fibonacci | ₹1,800.37 | ₹1,764.35 | ₹1,742.09 | ₹1,706.07 | ₹1,670.05 | ₹1,647.79 | ₹1,611.77 |
| Camarilla | ₹1,748.23 | ₹1,739.59 | ₹1,730.94 | ₹1,706.07 | ₹1,713.66 | ₹1,705.01 | ₹1,696.37 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+154.59%
1 Week
+0.29%
1 Month
+18.9%
3 Months
-0.14%
6 Months
+81.34%
1 Year
+147.4%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹169.69
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
19.32%
Net margin 15.48% × asset turnover 0.64x × equity multiplier 1.95x
Company Overview
Sector
Healthcare
Market Cap
₹27,764 Cr
P/E (TTM)
85.5
ROE
27.0%
Book Value
₹85.6
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 14 Nov 2026. Not investment advice.
TopFund Analysis
Rubicon Research Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 70/100. The strongest factor is Growth (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (27.0%); strong operating margin (24.0%); promoter holding is falling. Strong 3-year revenue growth (64.5%).
TopFund Score — Fundamentals Quality
70/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is expected to give good quarter
- +Company has delivered good profit growth of 52.0% CAGR over last 5 years
- +Company has a good return on equity (ROE) track record: 3 Years ROE 27.5%
- −Stock is trading at 19.6 times its book value
- −Promoter holding has decreased over last quarter: -8.51%
- −Working capital days have increased from 68.8 days to 104 days
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Regional Director returned fast-track merger application on Nov. 6, 2026; company may pursue NCLT route.
Transcript of Earnings Call -Q2 - FY 2026-27
Newspaper Publication for Q2 ended September 30, 2026 Financial Results
Audio recording of Q2 and half-year FY2026 earnings call available on website.
Revised Q2 FY26 IPO monitoring report shows Rs. 4,329.07 million utilized; no deviation from objects.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 296 | 313 | 358 | 352 | 412 | 476 | 514 | 534 | 576 |
| Expenses + | 234 | 244 | 286 | 273 | 318 | 367 | 395 | 405 | 432 |
| Operating Profit | 62 | 70 | 72 | 79 | 94 | 108 | 119 | 129 | 144 |
| OPM % | 21.0% | 22.0% | 20.0% | 22.0% | 23.0% | 23.0% | 23.0% | 24.0% | 25.0% |
| Other Income + | 3 | 0 | 0 | 1 | 1 | 4 | 3 | 6 | 2 |
| Interest | 7 | 8 | 12 | 11 | 11 | 10 | 10 | 9 | 11 |
| Depreciation | 8 | 9 | 10 | 10 | 12 | 12 | 12 | 15 | 18 |
| Profit before tax | 49 | 53 | 51 | 60 | 72 | 91 | 99 | 110 | 117 |
| Tax % | 30.0% | 28.0% | 29.0% | 27.0% | 25.0% | 20.0% | 22.0% | 23.0% | 23.0% |
| Net Profit + | 34 | 38 | 36 | 43 | 54 | 73 | 77 | 85 | 90 |
| EPS in Rs | 2 | 3 | 2 | 3 | 3 | 4 | 5 | 5 | 5 |
| Raw PDF | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | — | — | — | — | 39 | 52 | 43 | 52 | 40 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 263 | 315 | 314 | 394 | 854 | 1,284 | 1,754 | 2,100 |
| Expenses + | 182 | 223 | 353 | 375 | 699 | 1,020 | 1,354 | 1,600 |
| Operating Profit | 81 | 92 | -39 | 18 | 155 | 264 | 400 | 500 |
| OPM % | 31.0% | 29.0% | -12.0% | 4.7% | 18.0% | 21.0% | 23.0% | 24.0% |
| Other Income + | 18 | 10 | 17 | 25 | 18 | 4 | 8 | 14 |
| Interest | 6 | 9 | 10 | 19 | 31 | 37 | 42 | 41 |
| Depreciation | 18 | 29 | 34 | 36 | 39 | 37 | 45 | 57 |
| Profit before tax | 74 | 63 | -66 | -11 | 103 | 195 | 321 | 417 |
| Tax % | 33.0% | 51.0% | 2.0% | 53.0% | 12.0% | 31.0% | 23.0% | — |
| Net Profit + | 49 | 31 | -67 | -17 | 91 | 134 | 247 | 325 |
| EPS in Rs | 3 | 2 | -4 | -1 | 6 | 9 | 15 | 20 |
| Dividend Payout % | 2.0% | 2.0% | 0.0% | -2.0% | 0.0% | 0.0% | 10.0% | — |
| Sales growth | — | 20 | 0 | 26 | 117 | 50 | 37 | 46 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Reserves | 335 | 369 | 300 | 281 | 370 | 526 | 1,272 | 1,400 |
| Borrowings + | 30 | 93 | 175 | 320 | 425 | 418 | 311 | 501 |
| Other Liabilities + | 60 | 71 | 79 | 144 | 300 | 493 | 727 | 843 |
| Total Liabilities | 430 | 538 | 560 | 750 | 1,109 | 1,451 | 2,327 | 2,761 |
| Fixed Assets + | 157 | 188 | 193 | 199 | 307 | 327 | 532 | 803 |
| CWIP | 2 | 6 | 3 | 25 | 10 | 7 | 41 | 90 |
| Investments | 19 | 14 | 0 | 0 | 0 | 0 | 27 | 29 |
| Other Assets + | 252 | 330 | 364 | 526 | 793 | 1,118 | 1,728 | 1,839 |
| Total Assets | 430 | 538 | 560 | 750 | 1,109 | 1,451 | 2,327 | 2,761 |
| Equity Capital | 5 | 5 | 5 | 5 | 15 | 15 | 17 | 17 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 5 | 62 | -63 | -75 | 21 | 159 | 205 |
| Cash from Investing Activity + | -84 | -46 | -46 | -32 | -68 | -65 | -407 |
| Cash from Financing Activity + | 80 | 52 | 63 | 123 | 44 | -40 | 283 |
| Net Cash Flow | 1 | 67 | -45 | 16 | -4 | 54 | 81 |
| Free Cash Flow | -54 | -10 | -117 | -119 | -35 | 91 | -24 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 40 | 104 | 138 | -394 | 25 | 75 | 78 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|
| Public | 22.57% | 22.57% | 23.29% | 24.03% |
| Promoters | 59.99% | 59.86% | 59.76% | 51.25% |
| FII | 7.99% | 7.54% | 7.52% | 9.01% |
| DII | 9.45% | 10.02% | 9.43% | 15.73% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Rubicon Research Limited (this stock) | 27,764 | 85.5 | 19.59 | 27.0% |
| Neuland Lab Ltd. | 27,106 | 59.9 | 13.35 | 21.2% |
| Krishna Inst Of Med Sci L | 31,903 | 157.0 | 8.11 | 11.3% |
| Acutaas Chemicals Limited | 32,281 | 73.5 | 17.37 | 24.0% |
| Piramal Pharma Limited | 32,557 | — | 4.0 | -3.83% |
| Wockhardt Limited | 32,944 | 82.4 | 6.39 | 6.11% |
| Granules India Limited | 22,226 | 31.7 | 3.39 | 13.8% |
Which Mutual Funds Hold Rubicon Research Limited?
Frequently Asked Questions about Rubicon Research Limited
Rubicon Research Limited (RUBICON) closed at ₹1,722.3 on NSE on 19 November 2026, up 64.0 (3.86%) from the previous close.
Rubicon Research Limited trades on the NSE (National Stock Exchange of India) under the symbol RUBICON.
Rubicon Research Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 85.5.
Rubicon Research Limited has a dividend yield of 0.09%.
Rubicon Research Limited's 52-week high is ₹1,899.0 and its 52-week low is ₹609.0.
Rubicon Research Limited has a market capitalisation of ₹27,764 crore.
Rubicon Research Limited has a TopFund Quality Score of 70/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Rubicon Research Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.